A study published earlier this week in Nature Communications using claims data from the US Veterans Affairs (VA) Healthcare ...

The anticipated rollout of updated Covid vaccines this fall might be at risk after a change by Health and Human Services ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.

Under President Trump, the Food and Drug Administration may no longer approve seasonal COVID-19 vaccines updated for the ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...